Incannex Healthcare Halted, News Pending
On Thursday, RBC Capital Markets updated their assessment of Abbott Laboratories (NYSE:ABT), raising the price target on the company’s shares from $140.00 to $145.00. The firm continued to endorse an Outperform rating for the healthcare giant, which currently commands a market capitalization of $228 billion. According to InvestingPro data, Abbott’s stock has delivered an impressive 15.8% return year-to-date, trading near its 52-week high with characteristically low volatility.
The adjustment follows Abbott Labs’ first-quarter financial results, which showed a solid 8.3% year-over-year growth in underlying business, alongside double-digit growth in earnings per share (EPS). These results are particularly significant considering the company’s extensive revenue base of $42.3 billion. RBC Capital’s analyst highlighted the robustness of Abbott’s business fundamentals in the face of current macroeconomic conditions and manageable tariff risks. InvestingPro analysis reveals the company maintains a "GREAT" financial health score of 3.08, with strong profitability metrics and sustainable cash flows.
Abbott’s reaffirmation of its 2025 guidance, which already accounts for the impact of tariffs, was a key point of reassurance for investors. Without tariffs, the guidance would have been even higher. This confirmation contributed to a roughly 3% increase in Abbott’s stock price on Thursday.
RBC Capital’s analyst expressed optimism about Abbott’s ability to sustain high-single digit revenue growth and double-digit EPS expansion, even as it navigates through tariffs and sticks to its full-year guidance. Following the earnings call, the firm reiterated its positive stance on Abbott Labs, with the revised price target reflecting this sentiment.
Abbott Laboratories’ financial performance and RBC Capital’s subsequent price target increase reflect the company’s consistent strength in its operational results and strategic outlook. The company trades at a P/E ratio of 17.05 and has maintained dividend payments for 55 consecutive years, demonstrating long-term stability. For deeper insights into Abbott’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 top US stocks.
In other recent news, Abbott Laboratories reported strong first-quarter results for 2025, with a 6.9% year-over-year increase in organic sales, reaching $10.36 billion. The company’s MedTech segment was a standout performer, achieving a 12.6% growth, which surpassed several analysts’ expectations. Despite a slight miss on overall revenue due to weaker COVID-19 testing sales, Abbott’s earnings per share (EPS) exceeded forecasts, coming in at $1.09, compared to the consensus estimate of $1.07. Abbott reaffirmed its full-year 2025 guidance, projecting organic revenue growth between 7.5% and 8.5% and adjusted EPS in the range of $5.05 to $5.25.
Analyst firms have reacted to these developments with various adjustments to their price targets for Abbott. UBS maintained a Buy rating with a $148 price target, citing the strength of the MedTech business and effective tariff management. Piper Sandler raised its price target to $145, maintaining an Overweight rating, while Stifel adjusted its target to $135 but upheld a Buy rating. Oppenheimer increased its target to $140, maintaining an Outperform rating, and Raymond (NSE:RYMD) James raised its target to $142, also maintaining an Outperform rating.
These revisions reflect analysts’ confidence in Abbott’s strategic initiatives and its ability to manage challenges such as tariffs. Notable developments include the EU CE-Mark approval for Abbott’s PFA-VOLT catheter and ongoing trials for new technologies. Analysts have highlighted Abbott’s diversified portfolio and strong growth profile as key factors contributing to its favorable outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.